PubMed HealthSearch

Biomedical subjects

R R Lett

Publications and source records attributed to R R Lett.

4 recordsLinked to original sources

The comparison of injury severity instrument performance using likelihood ratio and ROC curve analyses.

BACKGROUND: The relative merits of injury severity instruments are often difficult to determine because the statistical techniques, study populations, and outcomes used in trauma research tend to obscure rather than elucidate differences in performance. OBJECTIVE: To describe the advantages of likelihood ratio and receiver operator characteristic (ROC) curve analyses and to demonstrate them using study populations and outcomes that facilitate instrument discrimination. MATERIALS AND METHODS: Previously published data on the performance of the "Injury Severity Score" and of four triage instruments in the prediction of mortality; paired comparison of two instruments in a previously unpublished trauma registry dataset; use of likelihood ratio and ROC analyses. MEASUREMENTS AND MAIN RESULTS: In a comparison of triage instruments this study clearly showed that CRAMS, PHI, and RTI, which contain nonphysiological information, have higher performance levels than the Revised Trauma Score (RTS), which is restricted to physiological information. Absolute performance gains of these instruments over the RTS ranged from 5.9% to 43.5%. This study also noted that the ISS performs equally well for blunt and penetrating trauma, and affirms concerns about the adequacy of its performance. CONCLUSIONS: Likelihood ratio and ROC curve analyses demonstrate differences in injury severity instrument performance that were obscured by less rigorous methods of comparison.

Humans

Induction of resistance to Schistosoma mansoni infection in mice by purified parasite paramyosin.

Freeze-thaw (FT)-disrupted schistosomula or their membrane extract induced significant resistance in mice to Schistosoma mansoni infection (34 and 25%, respectively) without the use of adjuvant. Antigens identified in schistosome extracts by sera from immunized animals were then evaluated for protective potential. Immunization with schistosomal antigens of 97 and 68-70 kD resulted in significant protection that was equivalent to that obtained by FT schistosomula. Since the 97-kD antigen was suggested to be parasite paramyosin, we used a biochemical technique to purify this muscle protein. Purified schistosome paramyosin ran as a single band on 10% SDS-PAGE and was recognized both by sera from mice immunized with FT schistosomula and a polyclonal antiserum raised against the 97-kD parasite protein. Preincubation of schistosome paramyosin with sera from mice immunized with FT schistosomula resulted in the removal of reactivity with the 97-kD protein in crude worm extracts. Paramyosin was identified by Western blotting to be in the tegument of schistosomula. The purified schistosome paramyosin resulted in significant protection in three separate experiments (24, 46, and 53%) without the use of adjuvant. Addition of BCG to paramyosin resulted in enhanced protection.

Animals

Isolation and characterization of a protective antigen for adjuvant-free immunization against Schistosoma mansoni.

A single, 68,000 m.w. glycoprotein antigen from adult Schistosoma mansoni was purified by immunoaffinity chromatography with the use of a newly developed, protective, anti-schistosome murine monoclonal antibody. Immunization with two doses of 0.5 microgram or 1 microgram of purified antigen, without adjuvants, afforded a mean 28% reduction in parasite recovery in CF1 mice, and 2-% reduction in parasite BALB/c mice. On immunoblotting, the 68,000 m.w. antigen was common to S. mansoni adults and schistosomula, whereas parasite eggs contained only cross-reacting low m.w. antigens of 19,100 and 16,000. Immunization resulted in the development of anti-antigen antibody and enhanced immediate cutaneous hypersensitivity to the 31-3B6 antigen. By contrast, delayed-type hypersensitivity and sensitization to circumoval granuloma formation were not observed in immunized mice. It was concluded that the 68,000 m.w. 31-3B6 antigen represents a candidate vaccine for adjuvant-free immunization against S. mansoni.

Animals